Loading...

Quest Diagnostics Incorporated

DGXNYSE
Healthcare
Medical - Diagnostics & Research
$177.83
$-0.82(-0.46%)

Quest Diagnostics Incorporated DGX Peers

See (DGX) competitors and their performances in Stock Market.

Peer Comparison Table: Medical - Diagnostics & Research Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
DGX$177.83-0.46%19.8B22.38$7.91+1.74%
DHR-PB$1,261.26-0.78%916.8B146.01$8.64+0.56%
TMO$410.92+0.07%155.6B24.15$17.06+0.40%
DHR$199.53-0.73%144.3B39.00$5.17+0.56%
IDXX$532.91+0.47%42.5B48.84$10.81N/A
A$119.36+0.62%33.9B29.42$4.06+0.81%
IQV$157.69-0.64%27.4B21.58$7.33N/A
MTD$1,185.61-0.61%24.8B29.81$40.04N/A
NTRA$168.65+2.73%23B-113.63-$1.48N/A
WAT$354.49+1.28%21.1B32.18$11.03N/A
Showing 1 to 10 of 89 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

DGX vs DHR-PB Comparison

DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DGX stands at 19.8B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, DGX is priced at $177.83, while DHR-PB trades at $1,261.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DGX currently has a P/E ratio of 22.38, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, DGX's ROE is +0.13%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, DGX is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.

Stock Price Comparison

Loading...

Frequently Asked Questions

;